ClinicalTrials.gg

Program

HB0017

A development code. Also written as “HB0017 Injection”, “HB0017 Q4W” and “HB0017 Q8W”.

Its studies are mostly in Psoriasis, led by Huabo Biopharm.

Furthest: phase 3, since Jun 18, 20245 company-led studies, 1 open or runningNext primary completion: Dec 31, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Huabo Biopharm51 open or runningphase 3since Jun 18, 2024Aug 4, 2020Dec 31, 2026phase 1 · NCT07920861

Also a collaborator on its studies: shanghai-huaota-biopharmaceutical-co-ltd.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 4, 2020First study: phase 1 study in Healthy SubjectsFirst studyNCT04505033 · 40 enrolled · New Zealand
  2. Aug 31, 2022Phase 2 study in Plaque PsoriasisNCT05531682 · 160 enrolled · China
  3. Jun 18, 2024Phase 3 study in PsoriasisNCT06477237 · 408 enrolled · China
  4. Sep 9, 2024Phase 2 study in PsoriasisNCT06592274 · 206 enrolled · China
  5. Oct 21, 2026Phase 1 study in PsoriasisNCT07920861 · 90 planned · China

Ahead

  1. Dec 31, 2026Primary completion: phase 1 study in PsoriasisNCT07920861

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07920861Psoriasis · China1RecruitingDec 31, 202690
NCT06592274Psoriasis · China2CompletedApr 30, 2025206
NCT06477237Psoriasis · China3CompletedNov 15, 2024408
NCT05531682Plaque Psoriasis · China2CompletedMay 23, 2023160
NCT04505033Healthy Subjects · New Zealand1CompletedJan 2, 202140

How it is read

Names in the registry

  • “HB0017”, 5 entries
  • “HB0017 Injection”, 1 entry
  • “HB0017 Q4W”, 1 entry
  • “HB0017 Q8W”, 1 entry

Codes read as this program: HB0017.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.